| ABSTRACT Objective:To systemically evaluate the clinical efficacy and safety of Kangai injection combined with FOLFOX chemotherapy regimen in the treatment of colorectal cancer.Methods:The databases such as PubMed, the Cochrane Library, Embase, CNKI, SinoMed, VIP, and Wanfang database were searched to collect the randomized controlled trials (RCTs) about Kangai injection combined with FOLFOX chemotherapy regimen for colorectal cancer since from establishment to October 2016. According to the Cochrane Reviewer's Handbook, two reviewers independently screened the literature, extracted the data and assessed the methodological quality of the included RCTs. Then the Meta analysis was performed by using RevMan 5.3 software.Results:A total of 13 RCTs involving 952 participants were included. In the Meta analysis, Kangai injection combined with FOLFOX chemotherapy regimen can be better than FOLFOX chemotherapy regimen alone in the treatment of colorectal cancer in respect of the total effective rate (RR=1.17, 95%CI: 1.01 1.35, P=0.03), and improvement in life quality (RR=2.06, 95%CI: 1.67 2.52, P<0.000 01). In addition, Kangai injection can reduce the incidence rate of adverse reactions. Conclusion: Our study showed that Kangai injection combined with FOLFOX chemotherapy regimen is beneficial in the treatment of colorectal cancer, while our conclusion should be confirmed by more well designed and large scale randomized controlled trials. |
